| Latest Forum Topics / Grand Venture |
 Post Reply
|
|
EXPANSION INTO THE MEDICAL INDUSTRY FOR GROWTH
|
|
|
Joelton
Supreme |
06-Jan-2021 09:08
|
|
x 0
x 0 Alert Admin |
Grand Venture Tech in talks with third party for potential share subscription
GRAND Venture Technology on Monday said it is in discussions with a third party regarding a potential subscription of new shares in the company.
The Catalist-listed manufacturing service provider also understands that the third party is in talks to potentially acquire shares from certain existing shareholders.
Grand Venture Tech said in a bourse filing that discussions are ongoing and the company has not made any decision or entered into any definitive agreements for the possible subscription.
It said there is no certainty or assurance that these discussions will progress beyond the current stage. It added that it will release a further announcement if there are any material developments which warrant disclosure according to obligations under listing rules.
|
| Useful To Me Not Useful To Me | |
|
HopeToBeRight
Member |
22-Oct-2020 10:53
Yells: "My only purpose is to make money with everyone" |
|
x 0
x 0 Alert Admin |
All I can say is....just by the company' s name, it is a ' grander' version of venture. Got a lot more potential. Recent financials show huge improvement due to higher demand for their 2 main line of products - (1) semi-con and (2) life-sciences/electronics. With covid ongoing and accelerated digitalisation in our economy, by now most should know the increasing demand trend for the above two items will just continue going up. Previous financials, their operating margins were affected due to lockdown. Next period financials hopefully will show improvement... meaning double whammy of persistent higher revenue and higher margins leading to even higher bottomline. If i recall correctly, they bought new property in malaysia near end Feb 2020 citing expansion of production capacity...then recently Oct incorporate new malaysian subsidiary for manufacturing activities. Signal to me that company is in fact experiencing higher volumes. As for life-sciences segment, they also get ISO certification which allows them to cater to new customers' more stringent requirements and will open up new customer channel. Expect china operations to just continue going up with recovery ... same for singapore - many news to boost manufacturing and our export data show improvement in semi-con, life science and electronics. Have been accumulating this and am vested already. Good luck and be patient if investing in this! |
| Useful To Me Not Useful To Me | |
|
|
|
|
johnnytanki
Member |
12-Aug-2020 22:58
|
|
x 0
x 0 Alert Admin |
Great leadership and their business have not been impacted by Covid-19 |
| Useful To Me Not Useful To Me | |
|
johnng
Supreme |
12-Aug-2020 17:11
|
|
x 1
x 0 Alert Admin |
Closing 32cents |
| Useful To Me Not Useful To Me | |
|
johnng
Supreme |
12-Aug-2020 15:42
|
|
x 0
x 0 Alert Admin |
https://s3-ap-southeast-1.amazonaws.com/investingnote-production-webbucket/attachments/76255859bf01f2179468e43677ad61790e66148b.pdf?1597193294 |
| Useful To Me Not Useful To Me | |
|
|
|
|
johnng
Supreme |
12-Aug-2020 15:31
|
|
x 0
x 0 Alert Admin |
Operations are normalisingThe group has not experienced any push-back or order cancellation of order due to the Covis-19 outbreak. However, given the ongoing pandemic and the US-China trade war, the group said it will monitor its strategy and cash flow carefully. In Jun 2020, the group obtained certification for ISO 13485:2016, an internationally certified quality management system specific to the medical devices industry, to cater to growing customer demand in this sector.Reiterate AddWe reiterate our Add call on Grand Venture Technology Ltd with a higher TP of S$0.36 (previously S$0.262) as we raise our revenue forecasts with the normalisation of thesupply chain. Our FY20-22F EPS are raised by 25.7-42.0%. Our target price is based on a 2.35x FY20F P/BV multiple(previously 1.76x),derived from the Gordon Growth Model (COE: 7.7% ROE: 15.5%). Downside risks include deterioration in customer demand dueto escalation of the Covid-19 outbreak. Re-rating catalysts includenormalisation of profit margin as supply chain disruptions are resolved. |
| Useful To Me Not Useful To Me | |